ABSTRACT
@#AIM:To evaluate the effect of the vault on corneal endothelial cells after implantation of central hole implantable lens(ICL)V4c without viscoelastic microincision.<p>METHODS: Prospective non-randomized controlled study. A total of 70 patients(137 eyes)with myopia who underwent ICL V4c implantation in our hospital from November 2017 to February 2018 were divided into low vault group(100μm<vault≤250μm, 37 eyes), medium vault group(250μm<vault≤750μm, 69 eyes)and high vault group(750μm<vault≤900μm, 31 eyes)according to the size of postoperative vault. After 1a of follow-up, the changes of corneal endothelial cell count and anterior chamber parameters were observed.<p>RESULTS:At 1wk after operation, the anterior chamber depth, anterior chamber volume and anterior chamber angle of the three groups were all decreased compared with those before operation(<i>P</i><0.05). There was no significant difference in corneal endothelial cell count among the three groups at different time points before and after surgery. The loss rate of corneal endothelial cells in the low vault group at 1wk, 3mo and 1a after surgery were about 1.2%, 1.5% and 1.7%, respectively. The loss rate of corneal endothelial cells in the middle vault group were about 0.5%, 0.7% and 1.0%, respectively. The loss rate of corneal endothelial cells in the high vault group were about 1.1%, 1.3% and 1.4%, respectively.<p>CONCLUSION:The vault in early period after ICL V4c implantation without viscoelastic microincision had no significant effect on corneal endothelial cells.
ABSTRACT
PURPOSE: To compare changes in anterior segment parameters after Nd:YAG laser capsulotomy in eyes that underwent either combined phacovitrectomy or cataract surgery. METHODS: This retrospective study enrolled 37 eyes of 35 patients with posterior capsular opacification treated with combined phacovitrectomy (group A), and 35 eyes of 32 patients with posterior capsular opacification treated with cataract surgery (group B). Anterior segment parameters, including anterior chamber depth (ACD), anterior chamber angle, and anterior chamber volume, were measured by a Pentacam before Nd:YAG laser capsulotomy and 1 hour, 1 day, 1 week, 1 month, and 3 months after this treatment. RESULTS: In the cataract surgery group, the ACD was significantly lower 1 day (3.75 ± 0.74 mm), 1 week (3.73 ± 0.24 mm), and 3 months (3.74 ± 0.33 mm) after Nd:YAG laser capsulotomy compared with the pretreatment value (4.20 ± 0.62 mm, p = 0.002). By contrast, the ACD did not change significantly over time in the combined phacovitrectomy group. The ACD differed significantly between the two groups at 1 week, 1 month, and 3 months after capsulotomy. There were no significant changes in the anterior chamber volume, anterior chamber angle, central corneal thickness, or pupil size from before to after capsulotomy in either group. A non-significant trend toward myopic shift was observed in group A (p = 0.072) and B (p = 0.055). CONCLUSIONS: The results of the present study may help determine the power of the intraocular lens in patients who underwent combined surgery or cataract surgery and who will receive Nd:YAG laser capsulotomy.
Subject(s)
Humans , Anterior Chamber , Cataract , Lenses, Intraocular , Pupil , Retrospective StudiesABSTRACT
@#AIM: To assess the changes in anterior chamber parameters and examine the factors associated with changes in the intraocular pressure(IOP)in individuals who have undergone phacoemulsification surgery.<p>METHODS: It was a longitudinal analysis of secondary clinical data collected from 105 non-glaucomatous eyes(of 82 patients)undergoing a cataract surgery. We studied the association between anterior chamber parameters, grade of cataract, demographics, and changes in the IOP over a period of 3wk. We also evaluated the association between the pressure-depth(PD)ratio and changes in the IOP during this time.<p>RESULTS: The mean age [standard deviation(SD)] of the 82 patients was 60.1(7.8)years. The mean SD IOP was 15.06(3.36)mmHg pre-operatively; it increased to 15.75(4.21)mmHg on day one(<i>P</i>=0.20). In the multifactorial models, the mean IOP was -1.715 \〖95% confidence intervals(<i>CI</i>): -2.795, -0.636\〗 mmHg on day 21(±5)compared with the pre-operative values. The anterior chamber depth(ACD), axial length, age, sex, and grade of cataract were not significantly associated with changes in the IOP. Each unit increase in the PD ratio was associated with an increase in the mean IOP by 1.289 mmHg(95% <i>CI</i>: 0.906, 1.671). After adjusting for pre-operative PD ratio, none of the other variables(ACD, axial length, temporal angle)were significantly associated with changes in mean IOP.<p>CONCLUSION: The PD ratio was the single most important factor associated with the changes in post-operative IOP over 3wk post surgery.
ABSTRACT
PURPOSE: To investigate anterior segment parameters in obese patients in comparison to healthy individuals. METHODS: Thirty-four obese subjects and 34 age-sex-matched healthy subjects were enrolled in this prospective cross-sectional study. Ophthalmological examinations including intraocular pressure (IOP), central corneal thickness (CCT), anterior chamber depth (ACD), anterior chamber volume (ACV), anterior chamber angle (ACA), and axial length (AL) measurements were performed on each subject. Height and weight of all subjects were recorded and body mass index (BMI) was calculated. RESULTS: IOP was significantly higher in the obese group (p = 0.003). The mean ACD in obese subjects was significantly lower than that in control subjects (p = 0.036). AL, ACV, ACA and CCT were not significantly different between the groups. There was a positive correlation between BMI and IOP (r = 0.404, p < 0.001). ACD and ACA were negatively correlated with BMI. CONCLUSIONS: IOP was significantly higher and ACD was significantly lower in obese subjects. AL, ACV, ACA and CCT were not significantly different between the groups. The impact of obesity on anterior chamber parameters should be further investigated.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Anterior Chamber/pathology , Cross-Sectional Studies , Intraocular Pressure/physiology , Obesity/diagnostic imaging , Prospective Studies , Tomography, Optical Coherence/methods , Tonometry, OcularABSTRACT
PURPOSE: To evaluate the changes of anterior chamber parameters and intraocular pressure (IOP) with Pentacam(R) after intravitreal injection. METHODS: A total of 76 eyes of 76 patients received an intravitreal injection of either triamcinolone acetonide (TA) or bevacizumab. Twelve patients were treated with an intravitreal injection of TA 0.1 ml, 16 patients were treated with an intravitreal injection of TA 0.05 ml, while the remaining 48 patients received a bevacizumab 0.05 ml injection. All patients underwent anterior chamber depth, anterior chamber angle, and anterior chamber volume evaluation with Pentacam(R) before and 5 minutes after injection. Additionally, IOP measurements were taken 5 minutes before and 5 minutes, 30 minutes, 1 hour and 1 day after injection. RESULTS: Anterior chamber depth, anterior chamber angle, anterior chamber volume, and IOP changes in patients receiving TA 0.1 ml were 0.4 +/- 0.11 mm, 10.2 +/- 4.1degrees, 33.7 +/- 5.9 mm3 and 18.8 +/- 12.1 mm Hg, respectively. Anterior chamber depth, anterior chamber angle, anterior chamber volume, and IOP changes in patients receiving TA 0.05 ml were -0.01 +/- 0.05 mm, 2.4 +/- 3.2degrees, 5.8 +/- 9.5 mm3 and 4.8 +/- 7.4 mm Hg, respectively. Anterior chamber depth, anterior chamber angle, anterior chamber volume, and IOP changes in patients receiving bevacizumab were 0.28 +/- 0.99 mm, 0.8 +/- 4.0degrees, 7.1 +/- 9.6 mm3 and 5.4 +/- 6.3 mm Hg, respectively. There was a significant difference between TA 0.1 ml and 0.05 ml. However, there was no significant difference between TA 0.05 ml and bevacizumab 0.05 ml. CONCLUSIONS: Because of similar anterior chamber parameters changes after 0.05 ml intravitreal injection with TA or bevacizumab, early period IOP increases due to intravitreal volume expansion. Intravitreal 0.05 ml injections do not require any other procedures for controlling IOP 30 minutes after injection.